Aidoc and Imbio partner to provide an AI solution to prioritise suspected PE


Aidoc and Imbio have announced a partnership intended to provide an end-to-end artificial intelligence (AI) solution for pulmonary embolism (PE), with the goal of ultimately improving efficiency and quality of PE detection and treatment.

“Achieving the value of AI in clinical practice requires end-to-end solutions which consolidate the various AI results and tailor their delivery to the clinical needs,” said Tom Valent Aidoc’s vice president of business development.

“Imbio and Aidoc have joined forces to develop a complete PE solution to radiologists and interventionalists, both in terms of the suite of relevant algorithms and a seamless workflow native to each type of physician.”

Aidoc’s US Food and Drug Administration (FDA)-cleared AI solution already provides real-time notifications of patients with suspected PE. Imbio’s quantitative imaging analysis is intended for use for the automatic calculation of RV/LV ratio.

The partnership is intended to provide thoracic radiologists and PE management programmes timely notification of PE cases combined with automated RV/LV ratio calculations to potentially improve patient severity assessment and expedite treatment.

“Automating and presenting RV/LV ratio measurements to PE intervention teams has the ability to aid in patient care,” said Mike Hostetler Imbio’s director of marketing and sales. “Combining this with Aidoc’s always-on AI platform is intended to trigger targeted alerts to the relevant physicians, enhancing the synchronisation of intervention teams and the quality of treatment provided to the patients.”

In the USA alone, up to 200,000 people a year die due to PE. Undetected or late detection of PE is one of the most common causes of preventable death in hospitalised patients. PE diagnosis can be highly challenging due to its variable and non-specific presentation, making AI-driven workflow triage potentially beneficial. Research has shown that early diagnosis and treatment may significantly improves outcomes and saves lives.

CAUTION: The combined Aidoc and Imbio product is an investigational device. Limited by Federal law to investigational use.


Please enter your comment!
Please enter your name here